"
Team:Uppsala/human-practice
From 2013.igem.org
(Difference between revisions)
| (One intermediate revision not shown) | |||
| Line 77: | Line 77: | ||
<li><a href="https://2013.igem.org/Team:Uppsala/metabolic-engineering">Metabolic engineering</a> | <li><a href="https://2013.igem.org/Team:Uppsala/metabolic-engineering">Metabolic engineering</a> | ||
<ul> | <ul> | ||
| - | <li><a href="https://2013.igem.org/Team:Uppsala/p-coumaric-acid"> | + | <li><a href="https://2013.igem.org/Team:Uppsala/p-coumaric-acid">p-Coumaric acid</a></li> |
<li><a href="https://2013.igem.org/Team:Uppsala/resveratrol">Resveratrol</a></li> | <li><a href="https://2013.igem.org/Team:Uppsala/resveratrol">Resveratrol</a></li> | ||
<li><a href="https://2013.igem.org/Team:Uppsala/lycopene">Lycopene</a></li> | <li><a href="https://2013.igem.org/Team:Uppsala/lycopene">Lycopene</a></li> | ||
| Line 98: | Line 98: | ||
<li><a href="https://2013.igem.org/Team:Uppsala/modeling" id="list_type1"><img class="nav-text" src="https://static.igem.org/mediawiki/2013/6/63/Uppsala2013_Modeling.png"></a> | <li><a href="https://2013.igem.org/Team:Uppsala/modeling" id="list_type1"><img class="nav-text" src="https://static.igem.org/mediawiki/2013/6/63/Uppsala2013_Modeling.png"></a> | ||
<ul> | <ul> | ||
| - | <li><a href="https://2013.igem.org/Team:Uppsala/P-Coumaric-acid-pathway"> | + | <li><a href="https://2013.igem.org/Team:Uppsala/P-Coumaric-acid-pathway">Kinetic model</a></li> |
<li><a href="https://2013.igem.org/Team:Uppsala/modeling-tutorial">Modeling tutorial </a></li> | <li><a href="https://2013.igem.org/Team:Uppsala/modeling-tutorial">Modeling tutorial </a></li> | ||
| + | |||
| + | <li><a href="https://2013.igem.org/Team:Uppsala/toxicity-model">Toxicity model</a></li> | ||
</ul></li> | </ul></li> | ||
<li><a href="https://2013.igem.org/Team:Uppsala/parts" id="list_type2"><img class="nav-text" src="https://static.igem.org/mediawiki/2013/e/eb/Uppsala2013_parts.png"></a></li> | <li><a href="https://2013.igem.org/Team:Uppsala/parts" id="list_type2"><img class="nav-text" src="https://static.igem.org/mediawiki/2013/e/eb/Uppsala2013_parts.png"></a></li> | ||
| Line 118: | Line 120: | ||
<li><a href="https://2013.igem.org/Team:Uppsala/public-opinion">Public opinion </a></li> | <li><a href="https://2013.igem.org/Team:Uppsala/public-opinion">Public opinion </a></li> | ||
<li><a href="https://2013.igem.org/Team:Uppsala/Outreach">High school & media </a></li> | <li><a href="https://2013.igem.org/Team:Uppsala/Outreach">High school & media </a></li> | ||
| - | + | <li><a href="https://2013.igem.org/Team:Uppsala/bioart">BioArt</a></li> | |
| + | <li><a href="https://2013.igem.org/Team:Uppsala/LactonutritiousWorld">A LactoWorld</a></li> | ||
| + | <li><a href="https://2013.igem.org/Team:Uppsala/killswitches">Killswitches</a></li> | ||
| + | <li><a href="https://2013.igem.org/Team:Uppsala/realization">Patent</a></li> | ||
</ul></li> | </ul></li> | ||
<li><a href="https://2013.igem.org/Team:Uppsala/attribution" id="list_type4"><img class="nav-text" src="https://static.igem.org/mediawiki/2013/5/5d/Uppsala2013_Attributions.png"></a></li> | <li><a href="https://2013.igem.org/Team:Uppsala/attribution" id="list_type4"><img class="nav-text" src="https://static.igem.org/mediawiki/2013/5/5d/Uppsala2013_Attributions.png"></a></li> | ||
| Line 196: | Line 201: | ||
<img src="https://static.igem.org/mediawiki/2013/e/e8/Uppsala2013_pic1.png" name="imageTag" /> | <img src="https://static.igem.org/mediawiki/2013/e/e8/Uppsala2013_pic1.png" name="imageTag" /> | ||
| - | <div style="position: relative; top: -440px; left: 230px; width:100px; height: 100px; z-index: 1000 | + | <div style="position: relative; top: -440px; left: 230px; width:100px; height: 100px; z-index: 1000;"> |
<a href="https://2013.igem.org/Team:Uppsala/realization" style="display:block;height:100%;width:100%;"></a> | <a href="https://2013.igem.org/Team:Uppsala/realization" style="display:block;height:100%;width:100%;"></a> | ||
</div> | </div> | ||
Latest revision as of 19:57, 27 October 2013
Human practice
This year, when we decided on our iGEM project, one of our main focuses was that it should be well integrated with our human practice projects. We think that human practice is one of the most important parts of iGEM.Our goal is to create GM food. To be able to realize our vision we have to consider alot of different aspects.
Is it safe to eat GM food?
Will people want to eat genetically engineered bacteria?
How can we easily communicate our project idea?
If we commercialize our idea, should we patent it?
Can we patent biobricks and do we even want that?
How should we see on safety issues, can our organism spread in the ecosystem? Should we add a killswitch?
Why is GMO restricted in Europe and what does politicians think of this?
Conclussion
We have tried to answer all of these questions in our human practice project. The conclussion we have made is that we think the future of GM food is bright and that it is absolutely realizable.
